Kinase by kinase in PAH

Spyrcel's broad kinase activity might explain link to PAH, unlike Gleevec

In the span of three weeks, cancer drugs Gleevec imatinib and Sprycel dasatinib have shown divergent signals in pulmonary arterial hypertension. Gleevec met the primary endpoint of treating PAH symptoms in a Phase III trial, while FDA updated Sprycel's label to include warnings of increased PAH risk. The likely reason the two tyrosine kinase inhibitors showed polar opposite activity is that Sprycel

Read the full 621 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE